Human adipose tissue mesenchymal stromal cells (AMSCs) share common traits, including similar differentiation potential and cell surface markers, with their bone marrow counterparts. Owing to their general availability, higher abundance and ease of isolation AMSCs may be convenient autologous delivery vehicles for localized tumor therapy. We demonstrate a model for tumor therapy development based on the use of AMSCs expressing renilla luciferase and thymidine kinase, as cellular vehicles for ganciclovir-mediated bystander killing of firefly luciferase expressing tumors, and noninvasive bioluminescence imaging to continuously monitor both, tumor cells and AMSCs. We show that the therapy delivering AMSCs survive long time within tumors, optimize the ratio of AMSCs to tumor cells for therapy, and asses the therapeutic effect in real time. Treatment of mice bearing prostate tumors plus therapeutic AMSCs with the prodrug ganciclovir induced bystander killing effect, reducing the number of tumor cells to 1.5 % that of control tumors. Thus, AMSCs could be useful vehicles to deliver localized therapy, with potential for clinical application in inoperable tumors and surgical borders after tumor resection. This approach, useful to evaluate efficiency of therapeutic models, should facilitate the selection of cell types, dosages, therapeutic agents and treatment protocols for cell-based therapies of specific tumors.
Introduction
There has been increasing interest in localized tumor therapies based on the use of suicide genes, generally enzymes that catalyze the conversion of a nontoxic prodrug into a cytotoxic agent, 1 introduced into cellular vehicles capable of delivering the toxic payload in the vicinity of the tumor cells.
By being able to localize the activation of toxic therapeutic agents in the proximity of the tumors target, suicide gene/prodrug combination strategies provide important advantages over classical chemotherapy, 1 in particular by reducing the required doses of potentially harmful agents and avoiding systemic toxicity to the host. It is believed that the diffusion of toxic gene products or activated prodrugs liberated following cell suicide through, for example, apoptotic vesicles, nearby gap junctions or through the transfer of hydrolases, 2 results in additional killing of neighboring cells (bystander effect), within the tumor and a further potentiation of the immune system response to tumor antigens liberated from dying cells. 3, 4 A frequently used suicide gene, for both, clinical and experimental applications, has been the herpes simplex virus thymidine kinase (TK), an enzyme with relaxed specificity, capable of phosphorylating a variety of nucleotide analogs, including ganciclovir (GCV), a synthetic analog of 2 0 -deoxyguanosine. 5 A truncated version of the viral TK (ttk) recently developed for imaging purposes by Ray et al. 6, 7 has shown increased TK activity and accumulation in the cytoplasm, together with lower cell toxicity, within other advantages. In this strategy, therapeutic effect is provided by the incorporation of the phosphorylated analog in the DNA of eukaryotic cells, which results in chain termination and cell suicide. 1, 8, 9 Clinical, 10, 11 and preclinical trials using suicide genes have been performed, in particular for brain tumors where surgery is frequently not possible [12] [13] [14] [15] [16] [17] and different types of TK-carrying vectors [18] [19] [20] have been developed with the aim of solving important limitations of this strategy such as inefficient and variable gene transfer, inaccurate tumor targeting, and transfection of nontumor cells. 21 There are few studies reporting the use of this approach against prostate tumors [22] [23] [24] [25] [26] Recent studies show that bone marrow mesenchymal stromal cells (MSCs) could be potential delivery vehicles of biologic anticancer agents, such as interferon-b (IFN-b), 27, 28 that migrate and home to invasive and metastatic tumors [29] [30] [31] [32] [33] even targeting microscopic ones. 34 However, the majority of accounts make no attempt to differentiate between casual retention and active homing mechanisms, to explain the presence of systemically inoculated MSCs in tumors. Moreover, there have been no reports documenting on quantitative aspects, such as the proportion, total number and accretion kinetic, of cell homing to tumors. 35 Adipose tissue-derived MSCs (AMSCs) express cell surface markers (CD105, CD73 and CD90), 29, 30 differentiation capacity [36] [37] [38] [39] and tumor homing ability 40 similar to those of bone marrow-derived MSCs. In addition, important advantages, such as ease of isolation, high abundance and lower extraction-associated risk for the donor suggest that these cells could be powerful autologous vehicles for a cell-based gene therapy-targeting tumors. 40 In this work, we sought to develop a model procedure to analyze the behavior and efficiency of cellular vehicle/ prodrug combinations used to deliver localized bystander therapy to tumors and apply it to explore the therapeutic potential of human AMSCs.
To do this, we used noninvasive bioluminescence imaging (BLI) to monitor in real time both, tumor cells and therapy vehicle cells, expressing different luciferase reporters. This strategy allowed us to explore some of the requirements for efficient bystander killing of a wellestablished human prostate tumor (PC3) model in immunodepressed mice using, so far untested, AMSCs expressing the ttk suicide gene as vehicles to deliver therapy. This approach should be of general application to the design and evaluation of cell-based cancer therapies.
Results

Viral transduction does not affect proliferation or differentiation potential of AMSCs
AMSCs transduced with either lentiviral vector Plox-G PLuc or hrl-mrfp-ttk showed no significant difference in cell proliferation capacity in comparison to untransduced cells (data not shown) and could be induced to differentiate in vitro to the adipose, cartilage and bone mesenchymal-derived cell lineages, staining positive for Oil Red O, toluidine blue and von Kossa, respectively (Supplementary Figure S1 ; Supplementary methods).
Survival of G PLuc-AMSCs in Rluc-PC3 tumors
Two groups of six mice were inoculated in each thigh with 5 Â 10 5 RLuc-PC3 cells alone or with the same number of RLuc-PC3 cells mixed with 5 Â 10 5 G PLucAMSCs and imaged by BLI to determine initial cell loads. Implanted mice were regularly monitored by BLI during a 6-week period to determine the proliferation of both tumor and therapeutic vehicle cells. BLI was performed as described, in two consecutive days to avoid overlap of the light signal from the two luciferases used.
Although the number of tumor cells increased during the 6-week period of the experiment (Figure 1b) , the number of inoculated G PLuc-AMSCs dropped by 60% in the first 2 weeks after implantation, stabilized at 10% of the initial value, between the second and third week after implantation, and remained stable until the end of the experiment (Figures 1a and c) .
Slightly higher numbers of tumor cells (P ¼ 0.236) were found in the 'mixed cell' tumors (RLuc-PC3 plus G PLuc-AMSCs) than in the control 'PC3 only' tumors (Figure 1e ), however, this was not accompanied by a detectable difference in tumor weight (Figure 1d ). Although small numbers of metastatic RLuc-PC3 cells were detected by a luminometric assay of luciferase activity in lungs, liver, bone and brain lysates in both groups of mice, there was no correlation between the number of metastatic cells and the presence or absence of AMSCs in the tumors. No migratory G PLuc-AMSCs could be identified in any of the tested organs (data not shown).
In vitro demonstration of bystander effect by hrl-mrfp-ttk-AMSCs
Replicates of AMSCs and hrl-mrfp-ttk-AMSCs were seeded in six-well plates and treated with either GCV or the same volume of phosphate-buffered saline (PBS). Live cells were counted daily using a hemocytometer and photographed on the fourth and seventh day after treatment (Figure 2a ). GCV treatment resulted in near 100% killing of the hrl-mrfp-ttk-AMSCs after 7 days, but had no effect on untransduced AMSCs. As expected, treatment of hrl-mrfp-ttk-AMSCs with saline had no effect either. Mortality of hrl-mrfp-ttk-AMSCs is graphically represented in (Figure 2b ).
Mixed cultures of untransduced PC3 and hrl-mrfp-ttk expressing AMSCs were also seeded in six-well plates and treated with either GCV or PBS. As seen in ( Figure  2c ) GCV treatment, but not PBS treatment, resulted in the killing of nearly 90% of neighboring untransduced PC3 cells, as would be expected due to bystander effect. Percentage of mortality is represented in (Figure 2d) .
Detection sensitivity for G PLuc-PC3 and hrl-mrfp-ttk-AMSCs in vivo
To correlate light measurements with the number of cells implanted, predetermined numbers of G PLuc-PC3 cells and hrl-mrfp-ttk-AMSCs were injected in the thigh muscles of mice and imaged by BLI after the administration of the corresponding luciferase substrate. The number of light events recorded was plotted, after background subtraction, vs the number of inoculated cells. As seen in (Figures 3a and c) (Figures 3b and d, respectively) .
Optimization of hrl-mrfp-ttk-AMSCs dose for in vivo bystander effect A total of 2.5 Â 10 5 G PLuc-PC3 cells were mixed with hrlmrfp-ttk-AMSC cells in several proportions (1:0.5, 1:1, 1:2; 1:3, 1:4 and 1:5) respectively, and then injected in the thigh muscle of mice. Beginning 1 week after the implantation, and during a 10-day period, the inoculated mice were treated daily by intraperitoneal (i.p.) administration of GCV (as described). Light production by PLuc and RLuc luciferases was monitored by BLI before the treatment As shown in (Figure 4a ), a clear killing effect proportional to the dose of hrl-mrfp-ttk vehicle cells could be detected by day 10 of treatment, at all the cell ratios tested. Quantitative analysis of the captured photon data showed that GCV administration resulted in a bystander G PLuc-PC3 cell killing that was almost linearly related to the ratio of vehicle to tumor cells, from the lowest 1:0.5 to the 1:4 (PC3: hrl-mrfp-ttk-AMSC) values (Figure 4b ). Further increase in the proportion of hrl-mrfp-ttk-AMSCs had no additional killing effect. Thus, the 1:4 PC3 to hrl-mrfp-ttk-AMSC proportion was adopted for use in the following experiments (Figure 4c ).
In vivo AMSCs-mediated tumor therapy
A total of 18 nude mice were inoculated in the right thigh (dorsal view) with 2. ). Subsequently, a treatment protocol was initiated that consisted of five consecutive 10-day periods beginning on days 0, 12, 24, 36 and 48, during which test mice (12 randomly chosen animals) received 2 daily doses of GCV, and control mice (6 remaining animals) received an equal volume of water. Coincident with the end of each treatment period, days 12, 24, 36, 48 and 60 all mice were imaged by BLI, as described previously. On days 24 and 48, when most of the hrl-mrfp-ttk-AMSCs initially implanted had been killed, additional inoculations of 1 Â 10 6 suicide cells were performed directly on the tumor mass. On day 48, in compliance with ethical committee requirements, all control mice, treated with water and 4 of the 12 mice treated with GCV, were killed due to the large size acquired by the tumors not inoculated with hrl-mrfp-ttk-AMSCs. The rest of the animals were continued in the treatment protocol with an additional hrl-mrfp-ttk-AMSCs inoculation plus 10-day treatment period and were killed at day 60.
Analysis of light events in BLI images showed that, within each of the 10-day treatment periods, administra- 
Discussion
There is an increasing interest in the use of cellular vehicles to deliver genes and therapeutic agents to tumors. 27, 28, 41 Although many of such studies have been performed using bone marrow MSCs, of demonstrated tumor homing capacity, 31, 34 only in one such study AMSCs were used as delivery vehicles for tumor therapy. 40 TK in combination with its prodrug GCV have been one of the most frequently used suicide genes in cancer therapy, either directly transduced into tumor cells or delivered by vehicle cells (suicide cells) to the tumor vicinity. Following the induction of GCV-mediated killing of vehicle cells, the uptake of products released by dead cells into neighboring tumor cells results in their death, also referred to as 'bystander' killing effect. There are few reports on the use of TK expressing MSCs as vehicles for cancer therapy, 42 in noninvasive imaging 34 or for preventive eradication of misbehaving cells, 43 and to this point there have been no reports on the use of AMSCs as vehicles of TK-based tumor therapy or their use in combination with BLI procedures to monitor therapeutic efficacy.
AMSCs have differentiation potential and cell surface markers similar to those of bone marrow MSCs [36] [37] [38] [39] and, as we have previously shown, when implanted in the thighs of mice can survive for long time, up to 8 months, without malignant transformation. 44 Owing to their Cell-based bystander therapy bioluminescence model M Vilalta et al easier isolation and high abundance in adipose tissue, the use of AMSCs as autologous antitumor therapy vehicles may offer considerable advantages over those of bone marrow MSCs. It has been claimed that MSCs can home to tumors and, therefore, can be used as systemically administered therapy vehicles. However, few attempts have been made to determine whether the presence of therapeutic cells in tumors results from the accidental retention of a few circulating cells or from an active homing mechanisms, or whether significant numbers of therapeutic vehicles can accumulate in tumors to have a therapeutic effect. 35 In previous studies, we have been unable to demonstrate by BLI homing of luciferase expressing AMSCs to tumors (M Vilalta et al., unpublished observation), although cells directly implanted into them were able to survive well during long times.
In general, some form of correlation between the number of therapeutic cells reaching a tumor and the number of tumor cell targets should be expected to attain a particular level of therapeutic effect. We reasoned that the design of cancer therapeutic strategies based on the delivery of cellular therapy vehicles to tumors would be facilitated by the capacity to monitor in real time the fate, location and abundance of both, therapy vehicles and their tumor cell targets. Such information would be valuable to rationalize the design of therapy for particular tumor types, and determine, for example, the number of therapeutic cells/tumor cell required for successful therapy using specific cell vehicle/prodrug combinations.
In this work, we demonstrate a model strategy to aid in tumor therapy development, based on the use of AMSCs as vehicles for the delivery of TK/GCV bystander killing effect, and in vivo BLI, to monitor the fate of tumor target and therapy vehicle cells. For this purpose, cells were transduced with lentiviral vectors for expression of either a chimeric polypeptide having mRFP, RLuc and TK activities or with a plox-G PLuc lentiviral vector for expression of the enhanced green fluorescent protein (eGFP) and PLuc genes. This approach has several advantages; the use of two We decided to use the thigh as implantation site for several reasons. PC3 cell line exhibits low testosterone-5-a reductase activities and is a hormone-independent tumor. Thus, orthotopic implantation in the prostate has little effect on its behavior. Also, in previous work from our group we have observed that growth rate and number of mobilized cells are, in fact, higher for the intramuscularly implanted tumors than for the orthotopically implanted ones (N Rubio et al., unpublished observation). A further consideration was that, as one of the main aims of this work was to generate a model to optimize therapeutic strategies against a variety of tumor types, it was important to have a common implantation site that would allow standardization of imaging conditions, as well as allow easy access for repeated therapeutic cell implantations, when necessary. Access to the prostate is difficult, and requires major surgery.
In preliminary in vitro tests we established that our hrl-mrfp-ttk expressing AMSCs were adequate vehicles for delivery of GCV-mediated therapy capable of efficiently killing tumor cells growing in their vicinity.
The use of BLI to analyze the in vivo behavior of AMSCs growing within PC3 tumors showed that, following implantation, AMSCs suffer a growth crisis resulting in the loss of up to 60% of the inoculated cells, a recurrent and cell-type-independent observation from many inoculation experiments (unpublished observation). However, the cell population surviving the initial implantation stage was able to survive thereafter until the end of the 6-week observation period. There was a slight, but not statistically significant (P40.05) tumor growth-promoting effect associated to the presence of the AMSCs in tumors. The use of BLI allowed us to optimize the ratio of suicide vehicles to tumor cells, by monitoring the response to GCV treatment of cell combinations, containing predetermined proportions of tumor and therapeutic vehicles, inoculated in the thighs of mice. With this approach it was possible to establish, in vivo, that cell killing increased in linear proportion to the vehicle cell dose up to a 1:4 ratio of tumor cells to therapy Cell-based bystander therapy bioluminescence model M Vilalta et al vehicles, past which, no further gains in killing capacity were attained. To model therapy, immunodepressed mice were implanted in the right thigh with G PLuc-PC3 tumor cells alone and, in the contralateral thigh of the same animal, with the previously established 1:4 optimum mixture of G PLuc-PC3 tumor cells to hrl-mrfp-ttk expressing AMSCs. In this manner, control and 'mixed cell' tumors could be subject to the same physiological and treatment environments, reducing inter-animal variability. The implanted cells were allowed an unperturbed 1-week period for tumor establishment, following which the mice were regularly treated with GCV and monitored by BLI to asses light production by both types of implanted cells. As GCV treatment results in the suicide of the cell used as therapy vehicles, additional doses of AMSCs were administered by injection at regular intervals to replenish the lost cells and sustain the therapeutic effect. This strategy was effective, and additional vehicle cell doses resulted in a progressive elimination of the tumor cells.
In control mice treated with water, comparison of light production by tumor cells in both thighs showed that AMSCs appear to have a slight, however not statistically significant, growth advantage over tumors without them, indicating that AMSCs may aid tumors. This effect also observed in our preliminary tests, is in agreement with previously described results suggesting that bone marrow MSCs contribute to tumor stroma 45, 46 and particularly to angiogenesis/lymphangiogenesis. 47 BLI monitoring of tumor and AMSCs during the GCV treatment showed a progressive decrease in the amount of light produced by tumor cells from mixed cell tumors containing AMSCs. By the end of the GCV treatment the number of PC3 cells in the mixed cell tumors was only 1.5% that in the contralateral 'PC3 only' control ones. Thus, GCV treatment resulted in a clearly detectable and quantifiable bystander effect on neighboring tumor cells. Owing to the large size of the control tumors, ethical considerations indicated the termination of the trial at this stage.
We also analyzed the capacity of the tumors implanted with and without therapeutic cells to metastasize to lungs, bone, brain, liver, spleen, skin and lymph nodes. To do this we measured luciferase activity in tissue homogenates using a very high sensitivity luminometric procedure capable of detecting as few as 5 and 122 cells in mouse lymph nodes and liver respectively. 48 Our results showed no difference in metastatic capacity between control tumors and mixed cell tumors. 
Cell-based bystander therapy bioluminescence model M Vilalta et al
In this study we show that AMSCs are convenient, autologous vehicles, capable of living within tumors for long times and of delivering efficient bystander killing to tumor cells. By direct inoculation of AMSCs expressing the ttk therapeutic gene into tumors, and noninvasive imaging of both cell types, we show that it is possible to determine the numbers of therapeutic cells required for a given degree of therapy.
Our data revealed that for this particular experimental tumor, effective cell-based tumor therapy may require a substantial proportion of therapeutic cells to tumor cells, which may be difficult to attain by procedures depending exclusively on homing of systemically implanted cellular vehicles. However, it is important to keep in mind that in this necessarily limited proof of principle study a particular experimental tumor and therapeutic cell/prodrug combination were used. Many other tumor models and therapeutic cell types in combination with several available prodrug systems, such as CD/5-FC, should be testable by this approach and may show to require considerably lower therapeutic cell/tumor ratios.
Nevertheless, direct inoculation of AMSCs expressing therapeutic genes into tumors could be a practical option in special situations where surgery is not possible.
Alternatively, therapeutic AMSCs could be used to treat surgery borders remaining after tumor removal to eliminate residual tumor cells. This is the first demonstration of a BLI-based strategy for the development of tumor therapies using real time dual monitoring of therapeutic effect on tumor cells and delivery vehicles that also allows control of tumor/ vehicle cell doses. This strategy should be of general application in preclinical studies to design antitumor therapies, including the identification of new types of cellular vehicles, agents, dosages and administration protocols. A nonviral construct, containing the RLuc from pRL-CMV vector (Promega, Madison, WI, USA) in pRC-CMV vector (Invitrogen, Carlsbad, CA, USA), was also used to perform permanent transfection to tumor cells.
Materials and methods
Vector constructs
Lentiviral particle production
Production of viral particles was performed using human embryonic kidney cells 293 T grown in DMEMhigh glucose (DMEM-hg) (Sigma, Steinheim, Germany), 10% heat-inactivated fetal bovine serum (FBS) (Sigma), 2 mM L-glutamine (Sigma), 50 U ml À1 penicillin/streptomycin (Sigma), and 2 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). The day previous to transfection, 3 Â 10 6 trypsinized cells were seeded on 10 cm 2 poly-D-lysine-(Sigma) treated plates. Each lentiviral transfer vector (15 mg), Plox-G PLuc and hrl-mrfpttk were mixed with viral envelope plasmid (pMD-G-VSV-G) (5 mg) and packaging construct (pCMV DR8.2) (10 mg), 450 ml of water, 50 ml of 2.5 M CaCl 2 and then mixed with 500 ml of HEPES-buffered saline solution 2 Â (pH 7) and incubated at room temperature (RT) for 20 min. This DNA solution was then added drop wise to the plate containing the 293 T cells plus medium, swirled gently and incubated for 16 h at 37 1C with 5% CO 2 . The following day, the transfection solution was removed, the cells were rinsed with PBS 1 Â and medium without FBS was added to the cells. Following a 48 h incubation the supernatant was collected, centrifuged at 2000 r.p.m. to remove cell debris, and filtered through a 0.45 mm low protein-binding filter (Corning, Bath, UK). The filtered supernatant was then loaded in thin wall polyallomer tubes and ultracentrifuged using the SW41.Ti rotor at 26 000 r.p.m. for 90 min at 4 1C in a L-100XP (Beckman Coulter, Fullerton, CA, USA) ultracentrifuge. The pellets were resuspended in PBS (+Mg 2+ ) and kept at À80 1C for storage. Virus titration was performed using the HIV-1 p24 antigen EiA (Beckman Coulter) 96 test kit.
AMSCs culture and transduction with lentivirus
Cells were seeded at a density of 5000 cells per cm 2 and grown in DMEM-hg, 10% heat-inactivated FBS (Hyclone, Logan, UT, USA), 2 mM L-glutamine (Sigma), 50 U ml 
Labeling PC3 tumor cells
The androgen-independent human prostate carcinoma cell line PC3 was purchased from ATCC (CRL-1435) and grown in a 1:1 mixture of Nutrient Mixture F-12 HAM and DMEM-hg (Sigma), containing 10% heat-inactivated FBS (Sigma), 2 mM L-glutamine (Sigma) and 50 U ml À1 penicillin/streptomycin (Sigma). PC3 cells were infected with Plox-G PLuc viral stock, as described above, and the highest 7.5% reporter expressing cells (G PLuc-PC3) were selected by FACS. For the experiment of AMSCs survival in tumors, PC3 cells were labeled using lipofectamine for a permanent transfection with the RLuc-pRC-CMV vector (RLuc-PC3).
Cell inoculation of nude mice
BALB/c homozygous nude nu/nu mice (6-week old) were purchased from Charles River (Wilmington, MA, USA) and maintained in a specific pathogen-free environment throughout the experiment. All animalrelated procedures were performed with the approval of the animal care committee of the Cardiovascular Research Center and the Government of Catalonia. Mice were anesthetized by i.p. injection of a mixture containing 100 mg kg À1 ketamine (Merial, Duluth, GA, USA) and 3.3 mg kg À1 xilacine (Henry Schein, Melville, NY, USA). For tumor inoculation, 5 Â 10 5 recently trypsinized G PLuc-PC3 or Rluc-PC3 cells suspended in 50 ml DMEM were injected intramuscularly (i.m.) in each thigh muscle, alone or in combination with hrl-mrfp-ttkAMSCs or G Á PLuc-AMSCs, respectively.
In vivo noninvasive BLI and image quantification
In vivo BLI of engrafted nude mice was performed as described previously.
14 In brief, mice were anesthetized and then injected i.p. with 150 ml of luciferin (PLuc substrate) (16.7 mg ml À1 in physiological serum) (Braun, Melsungen, Germany) or through tail vein with 25 ml of benzyl colenterazine (hCTZ) (RLuc substrate) (1 mg ml À1 in 50/50 propilenglycol/ethanol) (Nanolight Technology, Pinetop, AZ, USA, http://www.nanolight.com) diluted in 125 ml of water. Different substrates were inoculated in consecutive days. Thus, for monitoring, in all cases G Á PLuc-AMSCs were imaged in the first day after i.p. inoculation of luciferin, and the next day, RLuc-PC3 tumor cells were imaged after intravenous (i.v.) inoculation of colenterazine. For imaging, animals were placed at 216 mm from the camera objective in the detection chamber of a high-efficiency ORCA-2BT Imaging System (Hamamatsu Photonics, Hamamatsu City, Japan) provided with a C4742-98-LWG-MOD camera fitted with a 512 Â 512 pixel, charge couple device (CCD) cooled at À80 1C. Images were acquired during 5 min. An additional image of the animal was obtained using a white light source inside the detection chamber, to register the position of the luminescence signal. To increase detection sensitivity the readout noise of the recorded signal was reduced by adding the light events recorded by arrays of 8 Â 8 adjacent pixels (binning 8 Â 8) in the camera CCD (photons at 8 Â 8 and 1 Â 1 binning are interconvertible using the appropriate scaling factor). Mice were monitored during a 60-day period at the indicated times. Quantification and analysis of photons recorded in images was performed using the Wasabi image analysis software (Hamamatsu Photonics). To establish the ; 100 Â 10 3 ; 500 Â 10 3 and 1000 Â 10 3 of luciferaseexpressing cells grafted in the thigh muscle. Unless otherwise indicated, light measurements were expressed as PHCs vs number of grafted cells. The slope of the linear regression curve is the number of in vivo detected PHCs per cell. Pseudo color images were generated using arbitrary color bars representing standard light intensity levels for PLuc (blue ¼ lowest; red ¼ highest) and for RLuc (black ¼ lowest; blue ¼ highest). To calculate the number of PHCs from a selected area of interest, first the number of recorded PHCs was extracted from the image memory, then the same operation was performed for an area of the mouse image containing no implanted cells and the average number of PHCs per pixel was calculated using the Wasabi image analysis software (average background PHCs per pixel). The net number of PHCs in the area of interest was calculated using the formula: PHCs ¼ (total number of PHCs in the area of interest)À((number of pixels in the area of interest) Â (average background PHCs per pixel)).
Ganciclovir inoculation
GCV sodium (Cymevene À ) (Roche, Basel, Switzerland) was injected i.p. twice daily at a final dose of 100 mg kg À1 during 10 days. Controls were treated with injectable water with the same volume. 49, 50 For in vitro studies 1 Â 10 À6 mmol per cell of GCV was added to each well. 
